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Sir
We write in response to the editorial by MR Middleton regarding
the first analysis of the intergroup E1690 trial of high- and low-
dose interferon for high-risk melanoma conducted in the US
between 1990 and 1995. This large trial accrued 642 patients with
resectable deep primaries or node-positive disease to a three-arm
trial of observation, high-dose interferon a-2b (IFN-a-2b) for 1
year or low-dose IFN-a-2b for 2 years. The editorial was submitted
in February, after presentation of this trial’s preliminary analysis to
the ESMO in late 1998. But this study has now been presented in
much greater detail to the American Society of Clinical Oncology,
and is in review for publication. Middleton’s editorial concluded
that the high-dose regimen can not be recommended as the standard
of therapy for high-risk melanoma patients; however, this conclu-
sion is based on very incomplete information, since the data from
E1690 have yet to be fully presented in a formal publication. We
would like to correct a number of errors in the editorial, and urge
the community to carefully consider the data of the formal E1690
trial when they are published this year.
1. In reference to differences in overall survival between the study
population in the E1690 trial and the study population in the
preceding E1684 trial, Dr Middleton writes, ‘This unexpected
difference in the results of the two studies can be explained by
an improvement in the outcome of these patients kept under
observation … [and] may be due to changes in the staging and
surgical techniques: for example, sentinel – node mapping…’.
Response: The E1690 trial results differ most significantly from
E1684 in regard to post-relapse survival of patients in the observa-
tion arm, and this has nothing to do with differences in staging or
surgical technique. In point of fact, very few patients on E1690
were staged using sentinel lymph node biopsy, and none were
assessed as node-positive based on immunochemical or reverse-
transcriptase polymerase chain reaction analyses.
2. Dr Middleton also writes, ‘In the earlier trial, significant differ-
ences in overall survival were only seen amongst patients with
clinically apparent lymphadenopathy prior to resection.’
Response: Significant differences in overall survival in E1684
were seen in the intent-to-treat analysis of the entire population.
These differences, which were statistically significant for the
entire trial, were yet more significant in the histologically node-
positive population, which comprised 89% of the accrual to
E1684. In point of fact, the hazard ratio associated with high-dose
IFN-a-2 therapy on E1684 was greatest (indicating the most
improvement in survival) for patients with clinically negative but
pathologically positive nodes.
We would agree that the lack of efficacy of low-dose IFN-a
observed in the E1690 trial, coupled with the negative results of
the WHO 16 trial of low-dose adjuvant IFN lead to a compelling
conclusion that low-dose IFN-a-2b is less effective than the high-
dose regimen. We would also agree that ‘there seems little doubt
that high-dose interferon has an impact on melanoma, and can
delay the time to relapse in high risk melanoma patients.’
We believe that the consistent improvement in the continuous
relapse-free survival of high-risk melanoma patients receiving
high-dose IFN-a-2b seen in both E1690 and E1684 corroborates
the biologic activity of this regimen. With regard to the survival
benefit observed in E1684, this trial was conducted at a time when
IFN-a was not available for cross-over therapy, and all patients
treated on E1684 had undergone full lymphadenectomy and so had
no opportunity for cross-over. This situation is distinctly at variance
with E1690. In E1690, there was more than a twofold larger
number of patients with clinically negative but unresected
lymphatics, and these patients had the opportunity to cross-over to
IFN-a therapy if they had a regional nodal recurrence. In fact, they
did so in substantial numbers, asymmetrically pursuing IFN
salvage therapy from the observation arm after failure in regional
lymphatics. It is well recognized that regional lymph node relapse
is the most frequent site of relapse in melanoma patients who have
not undergone lymphadenectomy, and this occurrence in more than
40% of the total number of patients treated on E1690, provided an
opportunity for a confounding second exposure to IFN at relapse.
Such was not the case in E1684. A retrospective analysis of salvage
therapy demonstrated significantly greater numbers of patients
from the observation arm than from the high-dose IFN arm were
treated with IFN-a salvage therapy. This provides a plausible
explanation for the differences between the E1684 and E1690 trials
in terms of post-relapse and overall survival outcome.
We would urge the readership to review the data from E1690
when published in J Clin Oncology and to draw their own conclu-
sions. It is our responsibility as oncologists to present the data
regarding high-dose IFN-a-2b to our high-risk melanoma patients
fully and in a balanced fashion. Ultimately, it should be the
patient’s choice to accept or reject treatment.
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Adjuvant interferon in the treatment of melanoma —
reply
Sir
Although accepted for publication in February 1999 the editorial
in question was amended in proof to take into account Dr
Kirkwood’s presentation to the ASCO congress, as is made clear
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